news
Republicans and Democrats Agree: Pharmacy Benefit Managers Are a Problem
State and federal lawmakers are aligning to target Pharmacy Benefit Managers (PBMs), with two states already banning PBMs from owning pharmacies. This bipartisan push aims to reduce prescription drug costs and increase access for consumers. The move could reshape how people get their medications.
State and federal lawmakers are aligning to target Pharmacy Benefit Managers (PBMs), with two states already banning PBMs from owning pharmacies. This bipartisan push aims to reduce prescription drug costs and increase access for consumers. The move could reshape how people get their medications.
The architecture take
So, PBMs. It's wild to think that both sides of the aisle can agree on something, but here we are. This isn't about some niche regulatory tweak; it's about who controls the flow of medication into your body. When the company setting the price for your insulin or antidepressant also owns the pharmacy you have to buy it from, that's not a market — that's a bottleneck with a profit motive. It drives up prices, sure, but it also creates stress, delays, and often limits choice. I've heard too many stories of people driving miles for a specific medication because their plan only covers it at one chain. This kind of policy push could genuinely lower the cortisol load for anyone needing ongoing prescriptions, improving adherence and basic quality of life. Watch this space, because if more states follow, it'll force drug companies to compete on price, not on whose vertical integration game is stronger. That's a win for your nervous system and your wallet.